MRESVIA FDA Approval History
Last updated by Carmen Pope, BPharm on June 4, 2024.
FDA Approved: Yes (First approved May 31, 2024)
Brand name: mRESVIA
Generic name: respiratory syncytial virus vaccine, mRNA
Dosage form: Injection
Company: Moderna, Inc.
Treatment for: RSV
mRESVIA is a modified RNA vaccine that may protect adults aged 60 years and older from lower respiratory tract disease caused by an RSV infection.
mResvia is an injectable intramuscular vaccine that may be used to immunize adults aged 60 years and older against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV).
- Given as a single injection, usually into the deltoid muscle of the upper arm.
- mResvia is a modified RNA vaccine that encodes for the RSV F glycoprotein which induces an immune response and the formation of antibodies against RSV pre-F protein.
- It is the first mRNA vaccine to be approved for RSV and the third RSV vaccine to be approved overall.
Development timeline for mRESVIA
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
